1 minute reading time (154 words)

New Opportunities in Advanced KRAS Mutation–Positive NSCLC With D. Ross Camidge, MD, PhD, and Beth Sandy, MSN, CRNP, OCN®

An estimated 228,820 new cases of lung cancer are reported in the United States annually, and 135,720 people die of the disease (ACS, 2020). Approximately 84% of cases are classified as non-small cell. Most patients are diagnosed at a locally advanced or metastatic stage, making systemic therapy the cornerstone of management (ACS, 2020). Although 70% of patients receiving first-line classical doublet chemotherapy demonstrate clinical benefit, most develop progressive disease within 5 months of their final cycle (Lazzari et al, 2017). Recently, the use of tumor histology in determining optimal treatment strategies and relevant molecular biomarkers to further refine selection of novel therapies has improved outcomes for some patients. Unfortunately, the 5-year survival rate for patients with NSCLC remains a dismal 24%, indicating a need for continued research on more effective approaches to tumor control (ACS, 2020; NCI, 2019).

Related Posts

Copyright © Oncology Data Advisor. All rights reserved.